腹膜后肿瘤外科发展的历史、现状与前景展望

doi:10.16139/j.1007-9610.2022.06.02

外科理论与实践 ›› 2022, Vol. 27 ›› Issue (06): 490-494.doi: 10.16139/j.1007-9610.2022.06.02

腹膜后肿瘤外科发展的历史、现状与前景展望

陈骏, 罗成华()

北京大学国际医院腹膜后肿瘤外科，北京 102206

收稿日期:2022-09-28 出版日期:2022-11-25 发布日期:2023-01-30
通讯作者: 罗成华，E-mail: luochenghua@pkuih.edu.cn
基金资助:
北京市科技计划课题(Z221100007422042)

Past, present and prospect of retroperitoneal tumor surgery

CHEN Jun, LUO Chenghua()

Received:2022-09-28 Online:2022-11-25 Published:2023-01-30

摘要/Abstract

中图分类号:

R735.4

陈骏, 罗成华. 腹膜后肿瘤外科发展的历史、现状与前景展望[J]. 外科理论与实践, 2022, 27(06): 490-494.

CHEN Jun, LUO Chenghua. Past, present and prospect of retroperitoneal tumor surgery[J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 490-494.

参考文献 22

[1]	DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the United States[J]. CA Cancer J Clin, 2017, 67(4):261-272. doi: 10.3322/caac.21400 URL
[2]	Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy[J]. Cancer, 2006, 106(7):1610-1616. doi: 10.1002/cncr.21761 pmid: 16518798
[3]	Matsuda T, Won YJ, Chun-Ju Chiang R, et al. Rare cancers are not rare in Asia as well: the rare cancer burden in East Asia[J]. Cancer Epidemiol, 2020, 67:101702. doi: 10.1016/j.canep.2020.101702 URL
[4]	中华医学会肿瘤学分会, 中华医学会杂志社, 中国医师协会肛肠医师分会腹膜后疾病专业委员会, 等. 中国腹膜后肿瘤诊治专家共识(2019版)[J]. 中华肿瘤杂志, 2019, 41(10):728-733.
[5]	Donnelly BA. Primary retroperitoneal tumors; a report of 95 cases and a review of the literature[J]. Surg Gynecol Obstet, 1946, 83(6):705-717.
[6]	HJ W. Primary retroperitoneal sarcoma[J]. Am J Med Sci, 1903, 126:269-276. doi: 10.1097/00000441-190308000-00007 URL
[7]	Judd ES. Retroperitoneal tumors[J]. S Clin North Am, 1933,823.
[8]	Haas R, Stelmes JJ, Zaffaroni F, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: results from the EORTC 62092-22092 STRASS trial[J]. Cancer, 2022, 128(14):2796-2805. doi: 10.1002/cncr.34239 pmid: 35536104
[9]	Pack GT, Tabah EJ. Primary retroperitoneal tumors: a study of 120 cases[J]. Int Abstr Surg, 1954, 99(4):313-341. pmid: 13205424
[10]	Cody HS 3rd, Turnbull AD, Fortner JG, et al. The continuing challenge of retroperitoneal sarcomas[J]. Cancer, 1981, 47(9):2147-2152. pmid: 7226108
[11]	Storm FK, Mahvi DM. Diagnosis and management of retroperitoneal soft-tissue sarcoma[J]. Ann Surg, 1991, 214(1):2-10. doi: 10.1097/00000658-199107000-00002 pmid: 2064467
[12]	孟承伟, 胡永昌. 原发性腹膜后肿瘤:64例分析[J]. 中华外科杂志, 1960, 8(6)547-550.
[13]	陈凛, 李荣, 石怀银, 等. 原发性腹膜后肿瘤600例临床研究[J]. 中国肿瘤, 2003, 12(10):611-613.
[14]	Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients[J]. J Clin Oncol, 2009, 27(1):24-30. doi: 10.1200/JCO.2008.17.8871 pmid: 19047283
[15]	Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control[J]. J Clin Oncol, 2009, 27(1):31-37. doi: 10.1200/JCO.2008.18.0802 pmid: 19047280
[16]	Callegaro D, Miceli R, Brunelli C, et al. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma[J]. Br J Surg, 2015, 102(9):1079-1087. doi: 10.1002/bjs.9829 pmid: 26041724
[17]	Gronchi A, Miceli R, Colombo C, et al. Frontline exten-ded surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas[J]. Ann Oncol, 2012, 23(4):1067-1073. doi: 10.1093/annonc/mdr323 pmid: 21765179
[18]	MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Wor-king Group[J]. Ann Surg, 2018, 267(5):959-964. doi: 10.1097/SLA.0000000000002250 pmid: 28394870
[19]	Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321 URL
[20]	Istl AC, Gronchi A. Neoadjuvant therapy for primary resectable retroperitoneal sarcomas-looking forward[J]. Cancers(Basel), 2022, 14(7):1831.
[21]	Dickson MA, Tap WD, Keohan ML, et al. Phase Ⅱ trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma[J]. J Clin Oncol, 2013, 31(16):2024-2028. doi: 10.1200/JCO.2012.46.5476 pmid: 23569312
[22]	Mahmood ST, Agresta S, Vigil CE, et al. Phase Ⅱ study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous his-tiocytoma[J]. Int J Cancer, 2011, 129(8):1963-1969. doi: 10.1002/ijc.25843 pmid: 21154746

腹膜后肿瘤外科发展的历史、现状与前景展望

Past, present and prospect of retroperitoneal tumor surgery

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘文帅, 陆维祺, 周宇红. 腹膜后肉瘤诊疗规范、难点和发展方向——CSCO指南解读[J]. 外科理论与实践, 2022, 27(06): 483-489.
[2]	李成鹏, 郝纯毅. 积极推动我国腹膜后肉瘤临床研究开展的思考[J]. 外科理论与实践, 2022, 27(06): 495-499.
[3]	王征, 包慈航, 蒋国梁. 质子重离子放射治疗在腹膜后肉瘤治疗中的价值[J]. 外科理论与实践, 2022, 27(06): 506-510.
[4]	丁玉芹, 石洪成, 季正标. 影像学检查在腹膜后肿瘤诊治中的应用及相关专家共识解读[J]. 外科理论与实践, 2022, 27(06): 511-516.
[5]	杨传鑫, 王坚. 运用精准外科理念提高腹膜后肿瘤外科治疗的规范性与安全性[J]. 外科理论与实践, 2022, 27(06): 517-520.
[6]	邱法波, 周斌, 曲腾飞. 腹膜后肿瘤外科的规范及手术质量控制[J]. 外科理论与实践, 2022, 27(06): 526-529.
[7]	李倩玉, 奚豪, 韩冬艳, 蒋虹伟, 肖家诚,. 原发腹膜后黏液囊腺癌2例临床病理分析[J]. 诊断学理论与实践, 2015, 14(04): 348-352.
[8]	丁家增, 王俊青,. 腹膜后肿瘤累及腹腔重要血管时的手术策略[J]. 外科理论与实践, 2013, 18(05): 413-416.
[9]	王毅超,. 盆腔腹膜后肿瘤的外科处理与策略[J]. 外科理论与实践, 2012, 17(04): 320-324.
[10]	蒋俊豪, 陆维祺,. 腹部和腹膜后肿瘤手术时大血管的处理及重建[J]. 外科理论与实践, 2012, 17(04): 325-327.
[11]	王炯元, 朱隽, 练士贤, 童汉兴, 张勇, 柳菊, 陆维祺,. 腹部软组织平滑肌肉瘤外科治疗体会(附11例报告)[J]. 外科理论与实践, 2012, 17(04): 346-348.
[12]	赵如平, 姚伟强, 郭小毛,. 腹膜后软组织肉瘤放疗现状及研究进展[J]. 外科理论与实践, 2012, 17(04): 386-389.
[13]	郝玉娟, 罗成华,. 腹膜后脂肪肉瘤的诊治现状及进展[J]. 外科理论与实践, 2012, 17(04): 398-401.
[14]	师英强,. 重视腹腔及腹膜后肉瘤的诊治[J]. 外科理论与实践, 2012, 17(04): 297-300.
[15]	周建军, 曾蒙苏,. 腹膜后原发肿瘤CT和MR诊断现状[J]. 外科理论与实践, 2012, 17(04): 317-319.